Robert Hardi, MD
Gastroenterology · Chevy Chase, MDNPI 1285693440
Payments from drug & device makers
What this record shows
This record is dominated by speaking fees: $3,700 of the $5,198 with a category attached, or 71.2%. AbbVie accounts for 92.0% of it on its own, with 15 other manufacturers making up the rest. Reporting peaked in 2019 at $4,843 and has fallen 99.2% since, to $38 in 2025.
Across 39 payments — averaging $133.28 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AbbVie$5K
- Johnson & Johnson$49
- Shield Therapeutics Inc$48
- Bristol Myers Squibb$41
- Merck$37
- Salix Pharmaceuticals, A Division Of Bausch Health US, LLC$36
- plus $206 from 10 others
Across 15 payments — averaging $2870.14 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- AbbVie$22K
- Redhill Biopharma Inc.$13K
- Pfizer$8K
- Roche Products Limited$189
What the payments were for
- Speaking & faculty fees$3,70071%
- Travel & lodging$76015%
- Food & beverage$73814%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AbbVie(2 entities) | 15 | $4,782 |
| Johnson & Johnson | 2 | $49 |
| Shield Therapeutics Inc | 2 | $48 |
| Bristol Myers Squibb | 3 | $41 |
| Merck | 2 | $37 |
| Salix Pharmaceuticals, A Division Of Bausch Health US, LLC | 2 | $36 |
| Alnylam Pharmaceuticals Inc. | 2 | $32 |
| AstraZeneca | 2 | $31 |
| Takeda Pharmaceuticals U.S.A., Inc. | 2 | $21 |
| Sanofi | 1 | $21 |
| Phathom Pharmaceuticals, Inc. | 1 | $20 |
| Amarin Pharma, Inc. | 1 | $19 |
| Novo Nordisk | 1 | $19 |
| Boston Scientific | 1 | $16 |
| Pfizer | 1 | $14 |
| Boehringer Ingelheim | 1 | $12 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$5,198 in reported general payments places this provider in the 65th percentile of 455 gastroenterology providers in Maryland.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Sod Sulf-Potass Sulf-Mag SulfSodium, Potassium,mag Sulfates | 39 | $2,319 |
| Pantoprazole Sodium | 47 | $872 |
| Atorvastatin Calcium | 32 | $401 |
| ValacyclovirValacyclovir Hcl | 13 | $303 |
| Omeprazole | 27 | $298 |
| Celecoxib | 11 | $172 |
| Rosuvastatin Calcium | 11 | $54 |
| Simvastatin | 11 | $45 |
| Alprazolam | 11 | $24 |
Paid to pharmacies, not to this prescriber.
Other gastroenterology in Chevy Chase
- Zachary BormanChevy Chase$520K
- Erica CohenChevy Chase$385K
- Mohammed AliChevy Chase$49K
- Louis KormanChevy Chase$19K
- Apurva ModiRockville$1.1M
- Sergey KantsevoyBaltimore$1.1M
- Anurag MaheshwariBaltimore$803K
- Aline Charabaty PishvaianBaltimore$631K
- Mouen KhashabBaltimore$440K
- Natarajan RavendhranCatonsville$367K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.